Pharmaceuticals

Coherus Announces Initiation Of Phase 3 Trial Of CHS-0214 (Investigational Etanercept Biosimilar) In Rheumatoid Arthritis

REDWOOD CITY, Calif., June 24, 2014 /PRNewswire/ -- Coherus BioSciences, Inc. announced the start of its Phase 3 trial of CHS-0214, an investigational etanercept biosimilar, in rheumatoid arthritis (RA).  The Phase 3 trial is a randomized, double-blind, active-control, parallel-group, multicenter, g...

2014-06-24 06:57 2109

JHL Biotech Closes $35 Million Series B Financing

HSINCHU, June 20, 2014 /PRNewswire/ -- JHL Biotech, Inc., an emerging biopharmaceutical company, today announced that it has closed a Series B financing round of $35 million, led by new investors Milestone Capital and a consortium of Taiwan venture capitalists and individuals, including President In...

2014-06-20 02:30 2073

Neurim Pharmaceuticals Announces Publication of Positive Effects of Add-on Circadin(R) in Alzheimer's Disease Patients

TEL-AVIV, Israel, June 19, 2014 /PRNewswire/ -- Neurim Pharmaceuticals announced today publication of the results from an exploratory Phase 2 randomized placebo-controlled clinical trial evaluating the safety and efficacy of add-on Circadin® (Prolonged Release melatonin 2mg) to standard therapy in A...

2014-06-19 16:18 1875

AmVac Initiates Phase III Trial with its Lead Vaccine Gynevac for the Treatment of Bacterial Vaginosis

ZUG, Switzerland, June 18, 2014 /PRNewswire/ -- Swiss-based AmVac AG, a private biotech company focused on the development of innovative vaccines, announced today the initiation of a Phase III study with AmVac's lead vaccine Gynevac in Bacterial Vaginosis (BV). The trial aims to confirm the safety a...

2014-06-18 04:24 2215

TEENs Study Shows Achieving Target Blood Sugar Levels is Associated with Better Quality of Life for Young People with Type 1 Diabetes

PARIS, June 17, 2014 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) announced today the first results of the TEENs Registry Study, the largest contemporary real-world study of the care of nearly 6,000 young people with type 1 diabetes, ages 8 to 25. The findings not only highlighted that over ...

2014-06-17 01:32 1449

Sanofi's Lyxumia(R) (lixisenatide) Showed More Pronounced After-Test-Meal Blood Sugar Lowering Than Liraglutide When Both Were Added to Insulin Glargine

PARIS, June 17, 2014 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that Lyxumia® (lixisenatide) met the primary endpoint in an 8-week head-to-head pharmacodynamic study versus liraglutide, showing a significantly more pronounced post-prandial (after-meal) glucose (blood sugar)...

2014-06-17 00:33 1626

Fi Asia-China to Welcome the Global Food Industry to Shanghai this Month

AMSTERDAM, June 16, 2014 /PRNewswire/ -- China's leading nutritional ingredients event, Food ingredients (Fi) Asia China, Health ingredients (Hi) and Natural ingredients (Ni), will take place this month, June 26-28, 2014 in Shanghai, China. This is the premier event in China offering food & beverage...

2014-06-16 21:26 1365

Studies Show Investigational New Insulin Glargine Product from Lilly and Boehringer Ingelheim Similar in Safety and Efficacy to Lantus(R)

SAN FRANCISCO, June 16, 2014 /PRNewswire/ -- For the first time today, Eli Lilly and Company and Boehringer Ingelheim presented data showing that LY2963016, the alliance's investigational new insulin glargine product, has a similar safety and efficacy profile to currently marketed insulin glargine (...

2014-06-16 14:34 1178

Sanofi Announces Positive Phase 3 Results for Toujeo(R) (insulin glargine [rDNA origin] injection, 300 U/mL) in Japanese People with Uncontrolled Diabetes

PARIS, June 16, 2014 /PRNewswire/ -- - In EDITION JP I and II, investigational Toujeo(R)demonstrated similar blood sugar control with fewer night-time low blood sugar events over 6-month study period, vs. Lantus(R)- Sanofi (EURONEXT : SAN and NYSE : SNY) announced today full results from EDITION JP ...

2014-06-16 12:58 1127

Janssen Collaborates With ViiV Healthcare to Develop Two-Drug Single Tablet Regimen for the Maintenance Treatment of People Living With HIV

CORK, Ireland, June 12, 2014 /PRNewswire/ -- Janssen R&D Ireland Ltd announced today that they have entered into a collaboration with ViiV Healthcare to develop and commercialize a new single tablet regimen containing Janssen's Non-Nucleoside Reverse Transcriptase Inhibitor rilpivirine (marketed as ...

2014-06-12 23:24 1166

Milan District Court Confirms the Validity of Alfa Wassermann's Rifaximin-alpha Patents

BOLOGNA, Italy, June 12, 2014 /PRNewswire/ -- Normix® is the only authorized Gastrointestinal antibiotic based on Rifaximin-alpha. No generic version is allowed. With the judgment entered last April 18, the district court of Milan, Italy - the court having original jurisdiction on the matter -denied...

2014-06-12 16:02 1827

Varian Medical Systems Spotlights ProBeam® Compact Proton Therapy System at PTCOG 2014 Meeting in Shanghai

-- Varian co-sponsoring seminar on treating cancer with Intensity Modulated Proton Therapy at the Shanghai International Convention Center this week SHANGHAI, June 12, 2014 /PRNewswire/ -- Varian Medical Systems (NYSE: VAR), the world leader in radiotherapy equipment and software, is introducing the...

2014-06-12 03:38 2816

BioXcel Expands PharmGPS™ Platform to Facilitate the Design of Orphan Disease Treatments

Uniquely Positioned to Provide Big Data Analytics for  Over 6,800 Rare Diseases BRANFORD, Conn., June 11, 2014 /PRNewswire/ -- BioXcel Corporation, announced today its first-in-class cloud based Pharma big-data analytics platform, PharmGPSTM now has a dedicated Orphan Disease suite to aid in the dis...

2014-06-11 23:48 1117

Mundipharma and Genewel Sign Agreement Across Key Global Markets for Licensing and Promotion of Medifoam(R)

SINGAPORE, June 3, 2014 /PRNewswire/ -- Mundipharma has entered a strategic business partnership with Genewel for the licensing and promotion of Medifoam® (marketed as BETAplast® outside Korea), a moist wound dressing product. The alliance will see Mundipharma undertake responsibility for the succes...

2014-06-03 10:00 5683
1 ... 3637383940